Eagle Boston Investment Management Inc. purchased a new stake in Bio-Rad Laboratories (NYSE:BIO) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 825 shares of the medical research company’s stock, valued at approximately $206,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its position in shares of Bio-Rad Laboratories by 297.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 560 shares of the medical research company’s stock valued at $134,000 after purchasing an additional 419 shares during the last quarter. Private Advisor Group LLC purchased a new stake in shares of Bio-Rad Laboratories during the 4th quarter valued at $248,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Bio-Rad Laboratories by 42.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,165 shares of the medical research company’s stock valued at $278,000 after purchasing an additional 350 shares during the last quarter. Engineers Gate Manager LP purchased a new stake in shares of Bio-Rad Laboratories during the 1st quarter valued at $280,000. Finally, Advisory Services Network LLC increased its position in shares of Bio-Rad Laboratories by 218.6% during the 4th quarter. Advisory Services Network LLC now owns 1,217 shares of the medical research company’s stock valued at $290,000 after purchasing an additional 835 shares during the last quarter. 65.27% of the stock is owned by institutional investors and hedge funds.
Bio-Rad Laboratories opened at $291.66 on Monday, MarketBeat Ratings reports. The company has a quick ratio of 2.99, a current ratio of 4.33 and a debt-to-equity ratio of 0.10. The firm has a market cap of $8.69 billion, a PE ratio of 70.11, a PEG ratio of 3.17 and a beta of 0.95. Bio-Rad Laboratories has a fifty-two week low of $208.95 and a fifty-two week high of $293.43.
Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Tuesday, February 27th. The medical research company reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.22. The company had revenue of $620.43 million during the quarter, compared to the consensus estimate of $618.89 million. Bio-Rad Laboratories had a return on equity of 3.84% and a net margin of 34.32%. equities analysts forecast that Bio-Rad Laboratories will post 6.13 EPS for the current year.
Several equities research analysts have recently issued reports on the company. Zacks Investment Research lowered Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research report on Tuesday, May 8th. Jefferies Group raised their target price on Bio-Rad Laboratories to $325.00 and gave the company a “buy” rating in a research report on Wednesday, February 28th. ValuEngine raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. CL King lowered Bio-Rad Laboratories from a “buy” rating to a “neutral” rating in a research report on Friday, February 16th. Finally, Wells Fargo decreased their target price on Bio-Rad Laboratories from $290.00 to $280.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $297.20.
Bio-Rad Laboratories Profile
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.